Hyphens Pharma International eyes Catalist listing
IPO will comprise a cornerstone offering as well as a placement and a public offering
Add BT as a preferred source
Nisha Ramchandani
DeeperDive is a beta AI feature. Refer to full articles for the facts.
Singapore
HYPHENS Pharma International is seeking a listing on the Catalist board of the Singapore Exchange, with part of the proceeds from the inital public offering (IPO) to go towards expansion.
The pharmaceutical and consumer healthcare group's core business segments include speciality pharmaceutical products, proprietary brands such as Ceradan and Ocean Health supplements, as well as a wholesale medical hypermart and digital business.
Copyright SPH Media. All rights reserved.
TRENDING NOW
Air India asks Tata, Singapore Airlines for funds after US$2.4 billion loss
Beijing’s calculated silence on the Iran war
China pips the US if Asean is forced to choose, but analysts warn against reading it like a sports result
Richard Eu on how core values, customers keep Singapore’s TCM chain Eu Yan Sang relevant
